In 2020, Maria and ~ 478,000 others across Europe, were diagnosed with lung cancer. Maria was diagnosed with non-small cell lung cancer (NSCLC) with distant metastasis. She faces a terrifying 5-year survival rate of 6%. Devastatingly, Maria’s precious time left is tainted by the physical and emotional burden of her illness.
The patient described is fictional and has been used for illustrative purposes only.
SCLC is sometimes called oat cell cancer, and accounts for approximately 10–15% of lung cancer cases.
NSCLC accounts for ~80–85% of lung cancers. Depending on the type of cells that are cancerous, NSCLC can be categorised into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Most lung cancer deaths are due to advanced-stage adenocarcinoma and squamous cell carcinoma.
In 2020, there were 2.21 million new diagnoses and 1.79 million deaths caused by lung cancer worldwide.
Adapted from International Agency for Research/World Health Organization, 2020.
Adapted from International Agency for Research on Cancer/World Health Organization, 2020.
The median age of lung cancer diagnosis is 71, and most people are diagnosed above the age of 65.
In Western Europe, lung cancer is nearly twice as common in men than in women, although this gap has been closing over the past few decades.
Worldwide, twice as many men die from lung cancer than women.
To assess symptoms and possible risk factors
To determine signs of lung cancer as well as other health problems
To identify biomarkers and obtain a genomic profile of the cancer
A CT scan uses X-rays to make detailed cross-sectional images of the body. This technique helps to identify the shape, size, and position, of tumours.
Needles are often used to extract samples from suspected tumours. Techniques used include: transtracheal or transbronchial fine needle aspiration (FNA) or core biopsy involving a larger needle.
The fundamental structure of stage classification is the TNM system: T for characteristics of the primary tumour, N for nodal involvement, and M for (distant) metastasis. NSCLC stages range from 0 through to IV, the earliest stage is 0 (also called carcinoma in situ or CIS).
If lung cancer spreads to other parts of the body, it may cause bone pain or nervous system changes (such as headache, weakness or numbness of an arm or leg, dizziness, balance problems, or seizures), from cancer spread to the brain. It can also cause yellowing of the skin and eyes (jaundice), from cancer spread to the liver, or swelling of lymph nodes.
Lung cancer has an overall 5-year survival rate of 20.5%. Survival rates differ depending on the type and disease state at diagnosis:
Lung cancer is associated with not only a decreased chance of survival, but can also reduce quality of life for patients. This is as a result of the amount and severity of symptoms experienced having an impact on patients’ mental health, cognitive functioning, and physical abilities. It is therefore important that management of the disease incorporates maximising patients’ quality of life as well as overall survival.
We know that the words “you have cancer”, are terrifying for patients to hear and distressing for healthcare professionals to say. We also know that the precious time that cancer patients have left is often tainted by the physical and emotional burden of their illness. At Janssen Oncology, we are working tirelessly to transform outcomes and ensure healthcare professionals can help patients maximise the time they have left.
At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. It provides us with a constant source in which to channel our efforts, making us feel a part of something far bigger, outside ourselves.
Surgery, where possible, to remove the lung tumour.
Chemotherapy agents for the treatment of locally-advanced and metastatic lung cancer.
Radiation therapy, which can be used alongside chemotherapy to destroy the cancer cells, or instead of surgery in localised disease.
Immunotherapy, which can be used to help boost the patient’s immune response against the cancer.
Targeted therapies, which are designed to target a specific molecular feature of the cancer.
At Janssen Oncology, we know that change can only come through collaboration, so we invest our time and resources to partner with experts, unlocking the potential around us. All in pursuit of better outcomes for patients and their families. As a part of the Johnson & Johnson Lung Cancer Initiative, we are striving to address challenges across the entire patient pathway and ultimately transform outcomes for patients suffering from lung cancer.
Together, we have a deep and differentiated pipeline, including precision medicines, medical technologies improving lung cancer screening, and consumer health products encouraging smoking cessation.
Date of Preparation: June 2021 | CP-230384